

## Welcome to the Munich Biomarker Conference



In the Munich Biotech Cluster, the m<sup>4</sup> consortium brings together companies and academic institutions in Munich to realise the vision of „Personalized Medicine – a new dimension in drug development“ ([www.m4.de](http://www.m4.de)). Suitable biomarkers are the key to developing targeted and stratifying therapies, and it is becoming clear that such markers

will be crucial for market entry and success of new therapeutics in the future.

Therefore, the first Munich Biomarker Conference will focus on this topic and will showcase various local Biomarker research projects from the Munich area. The variety of indications covered at this event highlights how the concept of Personalized Medicine is not only important in oncology, but is also emerging in other fields. With a wide variety of methods and technologies, the conference will provide an excellent basis for new cooperations and synergies. A poster session and presentations of technology highlights from the industry will complete the programme.

I wish all participants an exciting and stimulating conference and many interesting discussions with colleagues and experts in the field.

Best regards,  
Horst Domdey

Bio<sup>M</sup> Biotech Cluster Development GmbH  
Spokesman of the Leading-Edge Cluster m<sup>4</sup>

### More Information

[www.m4.de/mbc](http://www.m4.de/mbc)

### Venue

Hilton Munich City Hotel  
Rosenheimer Straße 15  
81667 München

### Contact

Bio<sup>M</sup> Biotech Cluster Development GmbH  
Am Klopferspitz 19a  
82152 Martinsried

Phone +49 (0)89 89 96 79 0  
Fax +49 (0)89 89 96 79 79  
E-mail [info@bio-m.org](mailto:info@bio-m.org)  
Web [www.bio-m.org](http://www.bio-m.org)

Sponsored by:



# Munich Biomarker Conference

**Programme**

Nov 29th, 2011



[www.m4.de](http://www.m4.de)

managed by 

# 1st Munich Biomarker Conference

## Local Heroes and Global Challenges

Nov 29th, 2011

08:00 Registration

09:00 Welcome

Horst Domdey, Bio<sup>M</sup> Biotech Cluster Development GmbH

09:15 **Key Note**

**Personalized Healthcare Strategies in R&D**

Christian Meisel, Roche Pharma Research & Early Development, Penzberg

### DNA and RNA Biomarker

09:40 From NGS or Microarray High-Throughput

Data to Network-Based Patient Stratification

Thomas Werner, Genomatix Software GmbH

10:00 DNA-Promotor Methylation, Novel Biomarkers for Outcome

Prediction of Early and Advanced Breast Cancer Patients

Manfred Schmitt, Department of Obstetrics and Gynecology, Technische Universität München

10:20 Somatic Mutations in Acute Promyelocytic Leukemia (APL)

Identified by Exome Sequencing

Philipp A. Greif, Helmholtz Zentrum München - German Research Center for Environmental Health and Department of Medicine III, Ludwig-Maximilians-Universität München

10:40 Microvesicles for Non-Invasive Molecular Diagnostics

Mikkel Noerholm, Exosome Diagnostics GmbH

11:00 Coffee Break

### Imaging

11:30 MALDI Imaging Identifies Mitochondrial Proteins as Markers for the Prediction of Response to Neoadjuvant Chemotherapy in Barrett's Cancer

Mareike Elsner, Institute of Pathology, Helmholtz Zentrum München - German Research Center for Environmental Health

11:50 *In Vivo* Monitoring of tau in the Retina – a Novel Approach in the Diagnostic and Personalized Treatment of Alzheimer's Disease

Jochen Herms, Centre for Neuropathology, Ludwig-Maximilians-Universität München

12:10 Quantitative Pathology for the Development of Tissue-based Biomarkers: Methods and Use Cases

Martin Baatz, Definiens AG

12:30 Lunch

13:00 Poster Session

14:00 **Insight**

Personalized Medicine – Diversity of Approaches and Challenges for Realization

Urs Wiedemann, CEPTON GmbH

### Protein Biomarker

14:20 Antidepressant Drug Response -

From Pathways to Biosignatures

Christoph Turck, Max Planck Institute of Psychiatry

14:40 Co-expression of Phospho-HER2 and Phospho-HER3

Define a Novel Subgroup among HER2-negative

Breast Cancer Patients

Claudia Wolff, Institute of Pathology, Technische Universität München

15:00 switchSENSE – a Novel Biosensing Principle to Detect and Analyze Molecules on a Chip

Ulrich Rant, Walter Schottky Institut, Technische Universität München

15:20 Mass Spectrometry Based Phosphoproteomics – Mode of Action Analysis and Biomarker Identification for Targeted Drugs

Andreas Tebbe, Evotec Munich

15:40 Coffee Break

### Metabolomics

16:10 Detection of Autosomal Dominant Polycystic Kidney Disease Using a set of Urinary Biomarker

Wolfram Gronwald, Institute of Functional Genomics, University of Regensburg

16:30 Human Autologous Blood Cells as an Enabling Tool for Prediction of Individual Drug Toxicity – Metaheps for Metabolic Phenotyping

Andreas Benesic, Department of Internal Medicine II, University Hospital Großhadern, Ludwig-Maximilians-Universität München

16:50 Discovery of Novel Metabolomic Biomarkers for Progression of Chronic Kidney Disease

Ralph Zahn, Biocrates Life Sciences AG

17:10 **Key Note**

Towards Biomarker-Based Personalized Healthcare in Common Metabolic Diseases

Mark Broenstrup, Sanofi-Aventis Deutschland GmbH

17:30 Close of the Event

